Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer

The research group on adaptive image-guided radiotherapy for locally advanced cervical carcinoma completed the protocol for the EMBRACE II study in October 2018. This study will be carried out in the next few years at the University Clinic for Radiotherapy at the Medical University of Vienna and other international partner institutes. EMBRACE II builds on the findings of the current EMBRACE study. These are already implemented in everyday clinical practice in order to further improve the accuracy of the entire therapy of cervical carcinomas, using state-of-the-art techniques of tele- and brach

Trial Details

NCT ID
NCT03617133
Phase
PHASE2
Sponsor
Medical University of Vienna
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Increased use of IC/IS technique in BT
  • Reduction of vaginal source loading
  • Systematic utilisation of IMRT
  • Utilisation of daily IGRT (set-up according to bony structures)
  • EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring
  • EBRT dose prescription and reporting
Locations (sample)
  • Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including MRI guided BT
  • Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix.
  • Staging according to FIGO and TNM guidelines
  • MRI of pelvis at diagnosis is performed

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →